EP1470237A2 - Anticorps monoclonaux multifonctionnels diriges contre le peptidoglycane de bacteries gram-positif - Google Patents

Anticorps monoclonaux multifonctionnels diriges contre le peptidoglycane de bacteries gram-positif

Info

Publication number
EP1470237A2
EP1470237A2 EP02806494A EP02806494A EP1470237A2 EP 1470237 A2 EP1470237 A2 EP 1470237A2 EP 02806494 A EP02806494 A EP 02806494A EP 02806494 A EP02806494 A EP 02806494A EP 1470237 A2 EP1470237 A2 EP 1470237A2
Authority
EP
European Patent Office
Prior art keywords
mab
pepg
antibodies
antibody
gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02806494A
Other languages
German (de)
English (en)
Other versions
EP1470237A4 (fr
Inventor
Richard F. Schuman
John F. Kokai-Kun
Simon Foster
Jeffrey R. Stinson
Gerald W. Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosynexus Inc
Original Assignee
Biosynexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosynexus Inc filed Critical Biosynexus Inc
Publication of EP1470237A2 publication Critical patent/EP1470237A2/fr
Publication of EP1470237A4 publication Critical patent/EP1470237A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1296—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Listeria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • This invention in the fields of immunology and infectious diseases relates to protective antibodies that are specific for Gram-positive bacteria, particularly to bacteria bearing exposed peptidoglycan on the surface.
  • the invention includes monoclonal antibodies, as well as fragments, regions and derivatives thereof.
  • Man has long battled infections caused by bacteria, particularly Gram-positive bacteria.
  • the surface structures and cell wall of Gram-positive bacteria form a complex matrix that performs functions essential in bacteria and host interactions.
  • the cell wall consists of a peptidoglycan macromolecule (repeating units of N-acetylglucosamine and N-acetylmuramic acid) and attached accessory molecules including teichoic acids, lipoteichoic acids, and carbohydrates (see, e.g., (9) and (24)).
  • teichoic acids teichoic acids, lipoteichoic acids, and carbohydrates
  • there are many surface proteins anchored to the bacterial cell wall see, e.g., (17)).
  • the body employs a variety of means.
  • Opsonization may rely on a combination of antibodies and complement (the “classical pathway”), or just on complement (the “alternative pathway”).
  • the systems for opsonization and phagocytosis are significant because defective phagocytosis and killing of staphylococci (and other Gram-positive bacteria) leads to host invasion, infection and occasionally death.
  • the polyclonal serum from any mammal, including humans is likely to contain IgG that will bind to many different cell wall and surface components of Gram- positive bacteria.
  • IgGs may serve to protect against Gram-positive bacteria because polyclonal IgG binding to many epitopes on surface antigens or cell wall molecules (such as peptidoglycan, teichoic acid, lipoteichoic acid, proteins and carbohydrates) may collectively be opsonic and promote phagocytosis of Gram-positive bacteria.
  • the composite function of the antibodies in polyclonal serum may account for the serum's functional activity.
  • polyclonal serum cannot be used to elucidate the functional role of an antibody to a single epitope because, by definition, a polyclonal serum contains many different antibodies, which bind to multiple antigens and epitopes. Each antibody may contribute to the composite functional activity. Consequently, the ability of antibodies directed against specific epitopes on the cell wall to act as opsonic factors for Gram-positive bacteria is not defined.
  • the activity of serum raised against these preparations may not result from the activity of antibodies to peptidoglycan, but instead from the activity of antibodies to contaminates (see, e.g., (36)).
  • monoclonal antibodies to LTA that have multiple functional activities, including opsonic activity, against Gram-positive bacteria. These antibodies can be used to confirm that peptidoglycan preparations are free of LTA contamination.
  • This invention relates to therapeutic compositions comprising protective monoclonal antibodies (MAbs) to peptidoglycan (PepG) that enhance phagocytosis, block colonization and/or inhibit PepG induced- or facilitated-toxicity.
  • MAbs protective monoclonal antibodies
  • PepG peptidoglycan
  • phagocytosis is important for effective immunity against Gram-positive bacteria.
  • This invention provides protective opsonic MAbs to PepG that enhance phagocytosis and killing of Gram- positive bacteria and thus can block or treat systemic infections.
  • Nasal colonization has been shown to be a primary reservoir for staphylococci, and a strong correlation has been demonstrated between staphylococcal nasal colonization and subsequent staphylococcal infections.
  • This invention provides protective anti-PepG MAbs that block and/or alleviate nasal colonization by Gram-positive bacteria, such as staphylococci, and thereby reduce the incidence and/or severity of associated infections.
  • protective anti-PepG MAbs may reduce the toxic effects of cell wall components.
  • these therapeutic compositions both prevent and treat infections by Gram-positive bacteria.
  • the protective monoclonal antibodies of the invention include both IgG and IgM anti-PepG MAbs specific for PepG and include mouse, mouse/human chimeric, humanized or fully human MAbs specific for PepG.
  • the protective monoclonal antibodies of this invention are directed to any of the multiple epitopes on PepG. They exhibit multiple binding characteristics and functional activities.
  • These protective monoclonal antibodies can be administered singly or in combination into the nares of normal or colonized human subjects or other mammals to block or alleviate bacterial colonization of the nasal mucosa and to thereby preclude systemic infections or reduce the spread of Gram-positive bacteria.
  • the invention also includes methods of using both single protective anti-PepG MAbs and combinations of MAbs to enhance phagocytosis, inhibit bacterial infection, which may result from colonization of the nasal mucosa and reduce toxic effects of PepG and other cell wall components or toxins.
  • PepG epitopes or antigens and peptides that mimic those epitopes and antigens would be useful as vaccines to elicit opsonic antibodies to Gram-positive bacteria.
  • Figure 1 shows the cDNA cloning strategy for the heavy chain and light chain variable regions of M130.
  • Figure 2 shows the polypeptide and nucleic acid sequences of (A) the M130 antibody light chain variable region (SEQ ID NO: 1 and SEQ ID NO: 2) and (B) the M130 antibody heavy chain variable region (SEQ ID NO: 3 and SEQ ID NO: 4).
  • Figure 3 is shows the pJSB22 heavy chain expression plasmid.
  • Figure 4 shows the pJSB6 light chain expression plasmid.
  • Figure 5 shows the pLG1 bi-cistronic expression plasmid.
  • Figure 6 shows the binding of anti-human IgG to the mouse/human chimeric antibody A130.
  • Figure 7 shows the binding activity of the mouse/human chimeric antibody, A130, to S. aureus peptidoglycan.
  • antibody includes full-length antibodies and portions thereof.
  • a full-length antibody has one pair or, more commonly, two pairs of polypeptide chains, each pair comprising a light and a heavy chain. Each heavy or light chain is divided into two regions, the variable region (which confers antigen recognition and binding) and the constant region (associated with localization and cellular interactions).
  • a full-length antibody commonly contains two heavy chain constant regions (HC or CH), two heavy chain variable regions (HV or VH), two light chain constant regions (LC or CL), and two light chain variable regions (LV or VL) ( Figure 2).
  • the light chains or chain may be either a lambda or a kappa chain.
  • the antibodies include at least one heavy chain variable region and one light chain variable region, such that the antibody binds antigen.
  • variable region that comprises alternating complementarity determining regions, or CDRs, and framework regions, or FRs.
  • the CDRs are the sequences within the variable region that generally confer antigen specificity.
  • the invention also encompasses portions of antibodies which comprise sufficient variable region sequence to confer antigen binding.
  • Portions of antibodies include, but are not limited to Fab, Fab', F(ab') 2 , Fv, SFv, scFv (single-chain Fv), whether produced by proteolytic cleavage of intact antibodies, such as papain or pepsin cleavage, or by recombinant methods, in which the cDNAs for the intact heavy and light chains are manipulated to produce fragments of the heavy and light chains, either separately, or as part of the same polypeptide.
  • MAbs of the present invention encompass antibody sequence corresponding to human and non-human animal antibodies, and hybrids thereof.
  • the term "chimeric antibody,” as used herein, includes antibodies that have variable regions derived from an animal antibody, such as rat or mouse antibody, fused to another molecule, for example, a constant region domain derived from a human IgG, IgA, or IgM antibody.
  • a "Humanized antibody” has the variable regions altered (through mutagenesis or CDR grafting) to match (as much as possible) the known sequence of human variable regions.
  • CDR grafting involves grafting the CDRs from an antibody with desired specificity onto the FRs of a human antibody, thereby replacing much of the non-human sequence with human sequence. Humanized antibodies, therefore, more closely match (in amino acid sequence) the sequence of known human antibodies.
  • HAMA human anti-mouse antibody
  • the invention also includes fully human antibodies which would avoid the HAMA respose as much as possible.
  • the invention also encompasses "modified antibodies", which include, for example, the proteins or peptides encoded by truncated or modified antibody-encoding genes. Such proteins or peptides may function similarly to the antibodies of the invention.
  • Other modifications such as the addition of other sequences that may enhance an effector function, which includes the ability to block or alleviate nasal colonization by staphylococci, are also within the present invention.
  • Such modifications include, for example, the addition of amino acids to the antibody's amino acid sequence, deletion of amino acids in the antibody's amino acid sequence, substitution of one or more amino acids in the antibody amino acid sequence with alternate amino acids, isotype switching, and class switching.
  • an antibody may be modified in its Fc region to prevent binding to bacterial proteins.
  • the Fc region normally provides binding sites for accessory cells of the immune system. As the antibodies bind to bacteria, and coat them, these accessory cells recognize the coated bacteria and respond to infection. When a bacterial protein binds to the Fc region near the places where accessory cells bind, the normal function of these cells is inhibited.
  • Protein A a bacterial protein found in the cell membrane of S. aureus, binds to the Fc region of IgG near accessory cell binding sites. In doing so, Protein A inhibits the function of these accessory cells, thus interfering with clearance of the bacterium.
  • the Fc portion of the antibody of the invention may be modified to prevent nonspecific binding of Protein A while retaining binding to accessory cells (see, e.g., (10)).
  • the antibodies of the invention include full-length antibodies, antibody portions, chimeric antibodies, humanized antibodies, fully human antibodies, and modified antibodies and will be referred to collectively as "MAbs" unless otherwise indicated.
  • epitope refers to a region, or regions, of PepG that is bound by an antibody to PepG.
  • the regions that are bound may or may not represent a contiguous portion of the molecule.
  • antigen refers to a polypeptide sequence, a non-proteinaceous molecule, or any molecule that can be recognized by the immune system.
  • An antigen may be a full-sized staphylococcal protein or molecule, or a fragment thereof, wherein the fragment is either produced from a recombinant cDNA encoding less than the full-length protein, or a fragment derived from the full-sized molecule or protein or a fragment thereof. Such fragments may be made by proteolysis.
  • An antigen may also be a polypeptide sequence that encompasses an epitope of a staphylococcal protein, wherein the epitope may not be contiguous with the linear polypeptide sequence of the protein.
  • the DNA sequence encoding an antigen may be identified, isolated, cloned, and transferred to a prokaryotic or eukaryotic cell for expression by procedures well-known in the art (25).
  • An antigen may be 100% identical to a region of the staphylococcal molecule or protein amino acid sequence, or it may be at least 95% identical, or at least 90% identical, or at least 85% identical.
  • An antigen may also have less than 100%, 95%, 90% or 85% identity with the staphylococcal molecule or protein amino acid sequence, provided that it still is able to elicit antibodies that bind to a native staphylococcal molecule or protein.
  • the percent identity of a peptide antigen can be determined, for example, by comparing the sequence of the target antigen or epitope to the analagous portion of staphylococcal sequence using the GAP computer program, version 6.0 described by Devereux et al. (Nucl. Acids Res. 12:387, 1984) and available from the University of Wisconsin Genetics Computer Group (UWGCG) (40).
  • the GAP program utilizes the alignment method of Needleman and Wunsch (J. Mol. Biol. 48:443, 1970), as revised by Smith and Waterman (Adv. Appl. Math 2:482, 1981 ), and is applicable to determining the percent identity of protein or nucleotide sequences referenced herein (41 , 42).
  • the preferred default parameters for the GAP program include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non- identities) for nucleotides, and the weighted comparison matrix of Gribskov and Burgess, Nucl. Acids Res. 14:6745, 1986, as described by Schwartz and Dayhoff, eds., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358, 1979; (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps (43, 44).
  • the percent identity over a defined region of peptide or nucleotide sequence may by determined by dividing the number of matching amino acids or nucleotides by the total length of the aligned sequences, multiplied by 100%. Where an insertion or gap of one, two, or three amino acids occurs in a MAb chain, for example in or abutting a CDR, the insertion or gap is counted as single amino acid mismatch.
  • Antigens may be bacterial surface antigens and/or virulence and/or adherence antigens.
  • Virulence antigens are antigens that are accessible to an antibody when the antigen is in the configuration of the whole intact bacterium, i.e., the antigen is not inside the cell cytoplasm.
  • Virulence antigens are antigens that are involved in the pathogenic process, causing disease in a host. Virulence antigens include, for example, LTA, peptidoglycan, toxins, fimbria, flagella, and adherence antigens.
  • Adherence antigens mediate the ability of a staphylococcal bacterium to adhere to the surface of the nares.
  • An antigen may be a non-proteinaceous component of staphylococci such as a carbohydrate or lipid.
  • peptidoglycan and lipoteichoic acid are two non-proteinaceous antigens found in the cell wall of staphylococci.
  • Antigens may comprise or include fragments of nonproteinaceous molecules as long as they elicit an immune response.
  • antigens include molecules that can elicit an antibody response to PepG.
  • An antigen may be a PepG molecule, or a fragment thereof, wherein the fragment may be enzymatically, or otherwise, derived from the entire molecule or a fragment thereof.
  • An antigen may also be a fragment of PepG that encompasses an epitope of PepG, wherein the epitope may not be contiguous with the macromolecular structure of the molecule.
  • An antigen may be 100% identical to a region of PepG, or it may be 95% identical, or 90% identical, or 85% identical.
  • An antigen may also have less identity with the PepG molecule, provided that it is able to elicit antibodies that bind to PepG.
  • an antigen may also be an unrelated molecule, which, through some structural similarity, is able to elicit antibodies that bind to PepG.
  • an antigen elicits antibodies that bind to PepG on the surface of bacteria.
  • an antigen is a peptide that elicits antibodies that bind to PepG, and can be encoded by a cDNA. Procedures are generally described in Molecular Cloning: A Laboratory Manual, 2 nd Ed., which is herein incorporated by reference for any purpose (25). [038] Particular antigens of the invention include antigens that bind to any of the monoclonal antibodies produced by hybridomas 11-232.3, 11 -
  • An antibody is said to specifically bind to an antigen, epitope, or protein, if the antibody gives a signal by protein ELISA or other assay that is at least two fold, at least three fold, at least five fold, and at least ten fold greater than the background signal, i.e., at least two fold, at least three fold, at least five fold, or at least ten fold greater than the signal ascribed to nonspecific binding.
  • An antibody is said to specifically bind to a bacterium if the antibody gives a signal by, for example, methanol-fixed bacteria ELISA or live bacteria ELISA that is at least 1.5 fold, 2 fold, or 3 fold greater than the background signal.
  • Enhanced phagocytosis means an increase in phagocytosis over a background level as assayed by the methods in this application, or another comparable assay. The level deemed valuable may well vary depending on the specific circumstances of the infection, including the type of bacteria and the severity of the infection. For example, enhanced phagocytic activity may be equal to or greater than 75%, 80%, 85%, 90%, 95%, or 100% over background phagocytosis. Enhanced phagocytosis may also be equal to or greater than 50%, 55%, 60%, 65%, or 70% over background phagocytosis. As used herein, opsonic activity may also be assessed by assays that measure neutrophil mediated opsonophagocytotic bactericidal activity.
  • the MAb's of the invention are useful for the prophylaxis and other treatment of systemic and local staphylococcal infections.
  • a MAb of the invention is said to "alleviate" staphylococcal nasal colonization if it is able to decrease the number of colonies in the nares of a mammal when the MAb is administered before, concurrently with, or after exposure to staphylococci, whether that exposure results from the intentional instillation of staphylococcus or from general exposure.
  • a MAb or collection of MAbs is considered to alleviate colonization if the extent of colonization, or the number of bacterial colonies that can be grown from a sample of nasal tissue, is decreased after administering the MAb or collection of MAbs.
  • a MAb or collection of MAbs alleviates colonization in the nasal colonization assays described herein when it reduces the number of colonies by at least 25%, at least 50%, at least 60%, at least 75%, at least 80%, or at least 90%. 100% alleviation may also be referred to as eradication.
  • a MAb is said to "block" staphylococcal colonization if it is able to prevent the nasal colonization of a human or non-human mammal when it is administered prior to, or concurrently with, exposure to staphylococci, whether by intentional instillation or otherwise into the nares.
  • a MAb blocks colonization, as in the nasal colonization assay described herein, if no staphylococcal colonies can be grown from a sample of nasal tissue taken from a mammal treated with the MAb of the invention for an extended period such as 12 hours or longer or 24 hours or longer compared to control mammals.
  • a MAb also blocks colonization in the nasal colonization assay described herein if it causes a reduction in the number of animals that are colonized relative to control animals.
  • a MAb is considered to block colonization if the number of animals that are colonized after administering the material and the Gram-positive bacteria is reduced by at least 25%, at least 50%, and at least 75%, relative to control animals or if no colonies can be grown from a sample taken from a treated individual for an extended period such as 12 hours or 24 hours or longer.
  • a MAb "blocks" colonization if it prevents future colonization in human patients who show no signs of prior colonization for an extended period such as 12 hours or 24 hours or longer.
  • a MAb "alleviates” colonization if it causes a discernable decrease in the number of positive cultures taken from a human patient who is already positive for staphylococci before the MAbs of the invention are administered.
  • the MAbs of the invention may be administered intranasally to block and/or alleviate staphylococcal nasal colonization.
  • Administration (instillation) of an "effective amount" of the MAb results in a mammal that exhibits any of: 1 ) no nasal colonization by staphylococci for at least 12 hours after administration, 2) discernable, medically meaningful, or statistically significant decrease in the number of Gram-positive or staphylococcal colonies in the nares, or 3) a discernable, medically meaningful, or statistically significant decrease in the frequency of Gram- positive or staphylococcal cultures taken from the nares, or 4) a discernable, medically meaningful, or statistically significant decrease in the frequency of Gram-positive or staphylococcal infections.
  • distillation encompasses any delivery system capable of providing a effective amount of a MAb to the mammalian nares.
  • a goal of the invention is to reduce the frequency of staphylococcal infections, including nosocomial infections.
  • the administration of an effective amount includes that sufficient to demonstrate a discernable, medically meaningful, or statistically significant of decrease in the likelihood of staphylococcal infection involving a body site other than the nares, for example systemic infection, or infections at the site of trauma or surgery.
  • Such demonstrations may encompass, for example, animal studies or clinical trials of patients at risk of infection by Gram-positive bacteria, including, but not limited to: premature infants, persons undergoing inpatient or outpatient surgery, burn victims, patients receiving indwelling catheters, stents, joint replacements and the like, geriatric patients, and those with genetically, chemically or virally suppressed immune systems.
  • a "treatment" of a patient encompasses any administration of a composition of the invention that results in a "therapeutically beneficial outcome,” hereby defined as: 1) any discernable, medically meaningful, or statistically significant reduction, amelioration, or alleviation of existing Gram-positive bacterial infection or colonization, or 2) any discernable, medically meaningful, or statistically significant blocking or prophylaxis against future bacterial challenge, infection, or colonization, or 3) any discernable, medically meaningful, or statistically significant reduction in the likelihood of nosocomial infection.
  • Treatment thus encompasses a discernable, medically meaningful, or statistically significant reduction in the number of Gram-positive bacteria in a colonized or infected patient as well as a reduction in likelihood of future colonization or infection.
  • colonized refers to the subclinical presence of Gram-positive bacteria in patient, most particularly in the nares, whereas "infected” refers to clinical infection in any body site.
  • “medically meaningful” encompasses any treatment that improves the condition of a patient; improves the prognosis for a patient; reduces morbidity or mortality of a patient; or reduces the incidence of morbidity or rates of mortality from the bacterial infections addressed herein, among a population of patients.
  • the specific determination or identification of a "statistically significant" result will depend on the exact statistical test used.
  • One of ordinary skill in the art can readily recognize a statistically significant result in the context of any statistical test employed, as determined by the parameters of the test itself.
  • Examples of these well-known statistical tests include, but are not limited to, X 2 Test (Chi-Squared Test), Students t Test, F Test, M test, Fisher Exact Text, Binomial Exact Test, Poisson Exact Test, one way or two way repeated measures analysis of variance, and calculation of correlation efficient (Pearson and Spearman).
  • MAbs of the invention include "protective Mabs.”
  • Protective MAbs 1 exhibit strong binding to PepG, 2) enhance the opsonization and killing of Gram-positive bacteria (opsonophagocytic killing), and 3) reduce bacterial colonization.
  • Such MAbs may also inhibit the toxicity that is induced or facilitated by PepG.
  • these protective MAbs encompass therapeutic compositions for the treatment of Gram-positive infections.
  • a vaccine is considered to confer a protective immune response if it stimulates the production of protective opsonic antibodies to Gram-positive bacteria.
  • Production of protective opsonic antibodies may be measured by the presence of such antibodies in the serum of a test subject that has been administered the vaccine, relative to a control that has not received the vaccine.
  • the presence of protective opsonic antibodies in the serum may be measured by the activity assays described herein, or by other equivalent assays. If an opsonophagocytic bactericidal assay is used, then killing by the test serum of at least 50% more bacteria, 75% more bacteria, and at least 100% more bacteria, relative to the control serum, is considered to be enhanced immunity.
  • One aspect of the invention relates to protective anti-PepG MAbs that bind to whole bacteria.
  • Bacteria include all Gram-positive bacteria, and in particular, staphylococci and streptococci. Since many epitopes of PepG may be unavailable on the surface of Gram-positive bacteria, this invention provides protective MAbs that bind to whole bacteria as well as to isolated PepG. By binding PepG, these protective MAbs may neutralize the toxic effects of these molecules.
  • Another aspect of the invention relates to protective MAbs that function as opsonins, binding in a manner that allows interaction with phagocytes, thereby promoting phagocytosis.
  • Such protective MAbs may block or alleviate Gram-positive bacterial infections.
  • These protective anti- PepG MAbs may be used either alone or in combination with MAbs of different specificity, for example, MAbs specific for LTA, to treat diseases caused by Gram-positive bacteria and/or other organisms.
  • a further aspect of the invention is protective anti-PepG MAbs that may block or alleviate bacterial nasal colonization.
  • Particular embodiments of the invention include protective MAbs comprising the antigen-binding domains of the monoclonal antibodies MAb- 11-232.3, MAb-11 -248.2, MAb-11 -569.3, MAb-11-232.3 IE9, MAb-99- 110FC12 IE4, A130, or M130, described herein.
  • the invention also includes protective chimeric anti-PepG MAbs, in which the variable regions from a mouse monoclonal antibody are fused to human constant regions, and the chimeric antibody is produced in mammalian cell culture.
  • a chimeric heavy chain may comprise the antigen binding region of the heavy chain variable region of a protective mouse anti- PepG MAb of the invention linked to at least a portion of a human heavy chain constant region.
  • This chimeric heavy chain may be combined with a chimeric light chain that comprises the antigen binding region of the light chain variable region of a protective mouse anti-PepG MAb linked to at least a portion of a human light chain constant region.
  • a protective chimeric antibody is the human/mouse chimeric A130 antibody described herein.
  • a protective chimeric antibody comprises the antigen- binding domains of any of the monoclonal antibodies MAb-11 -232.3, MAb-11 - 248.2, MAb-11-569.3, MAb-11 -232.3 IE9, MAb-99-110FC12 IE4, A130, or M130, described herein.
  • Epitopes and antigens that are bound by protective anti-PepG monoclonal antibodies are also aspects of the invention. Further aspects of the invention include epitopes and antigens that elicit opsonic antibodies that bind to PepG of Gram-positive bacteria in vertebrates. These epitopes and antigens elicit protective opsonic antibodies when introduced into a human, a mouse, a rat, a rabbit, a dog, a cat, a cow, a sheep, a pig, a goat, or a chicken. Peptides that mimic those epitopes and antigens, and which can elicit opsonic antibodies to PepG of Gram-positive bacteria are also encompassed by the invention. These epitopes, antigens, peptides, and fragments of PepG may be used as vaccines to protect against, or alleviate, infections caused by Gram-positive bacteria.
  • the present invention also discloses therapeutic compositions comprising the protective anti-PepG MAbs of the invention, whether chimeric, humanized, or fully human, as well as fragments, regions, and derivatives thereof. These compositions may also include a pharmaceutically acceptable carrier.
  • the therapeutic compositions of the invention may alternatively comprise the isolated antigen, epitope, or portions thereof, together with a pharmaceutically acceptable carrier.
  • a therapeutic composition of the invention includes, but is not limited to, a protective antibody comprising the antigen-binding domains of any of the monoclonal antibodies MAb-11 -232.3, MAb-11-248.2, MAb-11-569.3, MAb-11-232.3 IE9, MAb-99-110FC12 IE4, A130, or M130, described herein.
  • Pharmaceutically acceptable carriers include, but are not limited to, sterile liquids, such as water, oils, including petroleum oil, animal oil, vegetable oil, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Saline solutions, aqueous dextrose, and glycerol solutions can also be employed as liquid carriers. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, 18 th Edition (8), which is herein incorporated by reference for any purpose.
  • the invention may be practiced with various delivery vehicles and/or carriers.
  • Such vehicles may increase the half-life of the Mabs in storage and upon administration including, but not limited to, application to mucus membranes, for example, upon inhalation or instillation into into the nares.
  • These carriers comprise natural polymers, semi-synthetic polymers, synthetic polymers, liposomes, and semi-solid dosage forms (8, 16, 22, 26, 29, 30, 37).
  • Natural polymers include, for example, proteins and polysaccharides.
  • Semi-synthetic polymers are modified natural polymers such as chitosan, which is the deacetylated form of the natural polysaccharide, chitin.
  • Synthetic polymers include, for example, polyphosphoesters, polyethylene glycol, poly (lactic acid), polystyrene sulfonate, and poly (lactide coglycolide).
  • Semi-solid dosage forms include, for example, dendrimers, creams, ointments, gels, and lotions. These carriers can also be used to microencapsulate the MAbs or be covalently linked to the MAbs.
  • the MAbs of the invention comprise, or are covalently or non-covalently bound to the outside of a carrier particle, which may be formulated as a powder, spray, aerosol, cream, gel, etc for application to the nares or infected area.
  • a carrier particle which may be formulated as a powder, spray, aerosol, cream, gel, etc for application to the nares or infected area.
  • the MAbs are coated onto a carrier particle core in a dissolvable film, which may comprise a mucoadhesive.
  • the carrier particle core may be inert, or dissolvable.
  • the invention further comprises any delivery system capable of providing a effective amount of a MAb to the mammalian nares or other infected area.
  • delivery system capable of providing a effective amount of a MAb to the mammalian nares or other infected area.
  • Representative and non-limiting formats include drops, sprays, powders, aerosols, mists, catheters, tubes, syringes, applicators for creams, particulates, pellets, and the like.
  • kits comprising a composition containing one or more MAbs of the invention, in connection with an appropriate delivery device or applicator for the composition, for example: catheters, tubes, sprayers, syringes, atomizers, or other applicator for creams, particulates, pellets, powders, liquids, gels and the like.
  • the present invention provides methods for treating a patient infected with, or suspected of being infected with, a Gram-positive bacteria.
  • the method comprises administering to a patient a therapeutically effective amount of a therapeutic composition comprising one or more of the protective anti-PepG MAbs (including monoclonal, chimeric, humanized, fully human, fragments, regions, and derivatives thereof) and a pharmaceutically acceptable carrier.
  • a patient can be any human or non-human mammal in need of prophylaxis or other treatment. Representative patients include any mammal subject to S.
  • aureus, staphylococcal, or Gram-positive infection or carriage including humans and non-human animals such as mice, rats, rabbits, dogs, cats, pigs, sheep, goats, horses, primates, ruminants including beef and milk cattle, buffalo, camels, as well as fur-bearing animals, herd animals, laboratory, zoo, and farm animals, kenneled and stabled animals, domestic pets, and veterinary animals.
  • non-human animals such as mice, rats, rabbits, dogs, cats, pigs, sheep, goats, horses, primates, ruminants including beef and milk cattle, buffalo, camels, as well as fur-bearing animals, herd animals, laboratory, zoo, and farm animals, kenneled and stabled animals, domestic pets, and veterinary animals.
  • a therapeutically effective amount is an amount reasonably believed to provide measurable relief, assistance, prophylactive or preventive effect in the treatment of the infection.
  • Such therapy as above or as described below may be primary or supplemental to additional treatment, such as antibiotic therapy for a Gram-positive bacterial infection, an infection caused by a different agent, or an unrelated disease.
  • Combination therapy with other antibodies is expressly contemplated within the invention.
  • a further embodiment of the present invention is a method of blocking or alleviating such infections, comprising administering an effective amount of a therapeutic composition comprising the protective anti-PepG MAb (whether monoclonal or chimeric, humanized, or fully human, including fragments, regions, and derivatives thereof) and a pharmaceutically acceptable carrier.
  • a therapeutic composition comprising the protective anti-PepG MAb (whether monoclonal or chimeric, humanized, or fully human, including fragments, regions, and derivatives thereof) and a pharmaceutically acceptable carrier.
  • An effective amount may be reasonably believed to provide some measure of blocking or alleviating infection by Gram-positive bacteria.
  • Such therapy as above or as described below may be primary or supplemental to additional treatment, such as antibiotic therapy, for a staphylococcal infection, an infection caused by a different Gram-positive bacterial agent, or an unrelated disease.
  • additional treatment such as antibiotic therapy, for a staphylococcal infection, an infection caused by a different Gram-positive bacterial agent, or an unrelated disease.
  • combination therapy with other antibodies is expressly contemplated within the invention.
  • a peptide that mimics any of the PepG epitopes would be useful to block binding of Gram-positive bacteria to epithelial cells and thereby inhibit colonization.
  • a therapeutic composition containing one or more such peptides may be administered intranasally to block or inhibit colonization, and therefore prevent or alleviate further infection.
  • Yet another embodiment of the present invention is a vaccine comprising one or more of the epitopes of the PepG antigen or one or more of the peptides that mimic a PepG epitope in a pharmaceutically acceptable carrier.
  • the vaccine elicits an antibody broadly protective and opsonic against infection by Gram-positive bacteria.
  • the vaccine may include the epitope, a peptide that mimics an epitope, any mixture of epitopes and peptides that mimic an epitope, the antigen, different antigens, or any combination of epitopes, peptides that mimic epitopes, and antigens.
  • the protective anti-PepG MAbs, vaccines, and therapeutic compositions of the invention are particularly beneficial for individuals known to be or suspected of being at risk of infection by Gram-positive bacteria, such as infant and elderly patients, immunocompromised patients, patients undergoing invasive procedures, patients undergoing chemotherapy, patients undergoing radiation therapy, and health care workers.
  • those at risk include zoo animals, herd animals, and animals maintained in close quarters.
  • the MAbs of the invention may be administered in conjunction with other antibiotic anti-staphylococcal drugs including antibiotics like mupirocin and bacitracin; anti-staphylococcal agents like lysostaphin, lysozyme, mutanolysin, and cellozyl muramidase; anti-bacterial peptides like nisin; and lantibiotics, or any other lanthione-containing molecule, such as nisin or subtilin.
  • antibiotics like mupirocin and bacitracin
  • anti-staphylococcal agents like lysostaphin, lysozyme, mutanolysin, and cellozyl muramidase
  • anti-bacterial peptides like nisin
  • lantibiotics or any other lanthione-containing molecule, such as nisin or subtilin.
  • the administration of the MAbs of the invention is within the know-how and experience of one of skill in the art in light of the particular formulation and delivery method selected.
  • the amount of MAbs required, combinations with appropriate carriers, the dosage schedule and amount may be varied within a wide range based on standard knowledge in the field without departing from the claimed invention.
  • the MAbs of the invention may be given by intravenous drip or in discrete doses, doses may range from 1 to 4 or more times daily giving 0.1 to 20 mg per dose.
  • the amount of MAb administered would be 2-4 times per day at 0.1-3 mg per dose, a dose known to be effective with an inoculum of 10 8 S.
  • aureus bacteria an amount of bacteria known to ensure 100% colonization in an animal model.
  • Such a dosing regimen would be effective on patients either admitted to the hospital for surgical procedures, patients suffering from various conditions that predispose them to staphylococcal infections, convalescing patients, infants with immature immune systems, or prior to a patients' release from hospitals.
  • the protective anti-PepG antibodies, vaccines, and the therapeutic compositions of the invention may be administered by intravenous, intraperitoneal, intracorporeal injection, intra-articular, intraventricular, intrathecal, intramuscular, subcutaneous, intranasally, dermally, intradermally, intravaginally, orally, or by any other effective method of administration.
  • the composition may also be given locally, such as by injection to the particular area infected, either intramuscularly or subcutaneously.
  • Administration can comprise administering the therapeutic composition by swabbing, immersing, soaking, or wiping directly to a patient.
  • the treatment can also be applied to objects to be placed within a patient, such as indwelling catheters, cardiac values, cerebrospinal fluid shunts, joint prostheses, other implants into the body, or any other objects, instruments, or appliances at risk of becoming infected with a Gram-positive bacteria, or at risk of introducing such an infection into a patient.
  • objects to be placed within a patient such as indwelling catheters, cardiac values, cerebrospinal fluid shunts, joint prostheses, other implants into the body, or any other objects, instruments, or appliances at risk of becoming infected with a Gram-positive bacteria, or at risk of introducing such an infection into a patient.
  • S. aureus, type 5 is deposited at the ATCC under Accession No. 49521.
  • S. aureus type 8 is deposited at the ATCC under Accession No. 12605.
  • Hybridoma 96-105CE11 IF6 (M110) was deposited at the ATCC on June 13, 1997 under Accession No. HB-12368.
  • Hybridoma 99-110 FC12 IE4 was deposited at the ATCC on September 21 , 2000 under Patent Deposit PTA-2492.
  • Hybridoma 11-232.3 IE9 (M130) was deposited at the ATCC on August 21 , 2001 under PTA-3659. Isotype Determination Assay
  • Isotype was determined using a mouse immunoglobulin isotype kit obtained from Zymed Laboratories (Cat. No. 90-6550). Binding Assays
  • immunoglobulin is incubated with a preparation of whole cell staphylococci or with a preparation of bacterial cell wall components such as LTA or PepG.
  • the binding assay may be an agglutination assay, a coagulation assay, a colorimetric assay, a fluorescent binding assay, or any other suitable binding assay that is known in the art.
  • a particularly suitable assay is either an enzyme-linked immunosorbent assay (ELISA) or a radio-immunoassay (RIA). Binding is detected directly and can also be detected indirectly by using competitive or noncompetitive binding procedures known in the art.
  • the whole cell staphylococcus preparation, LTA preparation, PepG preparation, or a combination of those preparations, may be fixed using standard techniques to a suitable solid support, including, but not limited to, a plate, a well, a bead, a micro-bead, a paddle, a propeller, or a stick.
  • Solid supports may be comprised of, for example, glass or plastic. In certain embodiments of the invention, the solid support is a microtiter plate.
  • a binding assay requires the following steps. First, the fixed preparation is incubated with an immunoglobulin source.
  • the immunoglobulin source is, for example, tissue culture supernatant or a biological sample such as ascites, plasma, serum, whole blood, or body tissue.
  • the immunoglobulin may be further isolated or purified from its source by means known in the art, and the purified or isolated immunoglobulin is subsequently used in the assay.
  • the amount of binding is determined by comparing the binding in a test sample to the binding in a negative control.
  • a negative control is defined as any sample that does not contain antigen-specific immunoglobulin.
  • a positive binding reaction results when the amount of binding observed for the test sample is greater than the amount of binding for a negative control.
  • Positive binding may be determined from a single positive/negative binding reaction or from the average of a series of binding reactions.
  • the series of binding reactions may include samples containing a measured amount of immunoglobulin that specifically binds to the fixed antigen, thereby creating a standard curve. This standard curve may be used to quantitate the amount of antigen-specific immunoglobulin in an unknown sample.
  • antibodies are fixed to a solid support and an unknown immunoglobulin sample is characterized by its ability to bind a bacterial preparation.
  • LBE Live Bacteria ELISA
  • the supernatant was removed and the bacteria were resuspended in 35-45 ml of phosphate buffered saline containing 0.1% bovine serum albumin (PBS/BSA).
  • PBS/BSA phosphate buffered saline containing 0.1% bovine serum albumin
  • the bacteria were again pelleted by centrifugation, the supernatant discarded and the bacteria resuspended in PBS/BSA to a percent transmittance (%T) of 65%-70% at 650 nm. From this suspension the bacteria were further diluted 15-fold in sterile 0.9% sodium chloride (Sigma cat. no. S8776, or equivalent), and 100 ⁇ l of this suspension was added to replicate wells of a flat-bottomed, sterile 96-well plate.
  • Each antibody to be tested was diluted to the desired concentration in PBS/BSA containing 0.05% Tween-20 and horse radish peroxidase-conjugated Protein A (Protein A-HRP, Zymed Laboratories) at a 1 : 10000 dilution (PBS/BSA/Tween/Prot A-HRP).
  • the Protein A-HRP was allowed to bind to the antibodies for 30-60 minutes at room temperature before use, thereby generating an antibody-Protein A-HRP complex to minimize the potential non-specific binding of the antibodies to the Protein A found on the surface of S. aureus..
  • several dilutions of test antibody were used in each assay.
  • the bacteria-coated plates were washed four times with phosphate buffered saline containing 0.05% Tween- 20 (PBS-T) as follows. Approximately 250 ⁇ l of PBS-T was added to each well. The buffer was removed by flicking the plate over the sink and the remaining buffer removed by inverting the plate and tapping it on absorbent paper. The antibody was diluted in PBS-T and then added to the wells. Supernatants, ascites, or purified antibodies were tested at the dilutions indicated in the Examples. Control wells received PBS-T alone. After addition of the antibody, the wells were incubated at room temperature for 30- 60 minutes in a draft-free environment.
  • PBS-T phosphate buffered saline containing 0.05% Tween- 20
  • the wells were again washed four times with PBS-T.
  • Ninety-five microliters of detection antibody was then added to each well.
  • the detection antibody was one of the following: rabbit anti-mouse lgG 3 , rabbit anti-mouse IgM, or goat anti-human IgG (gamma- specific), all conjugated to horse radish peroxidase (HRP) and diluted 1 :6000 in PBS-T (Zymed catalog numbers 61 -0420, 61-6820 and 62-8420, respectively).
  • Immunoassay with Protein A In order to evaluate the binding of the MAbs to S. aureus, the immunoassay procedure was modified for methanol-fixed bacteria, described above. Because S. aureus expresses Protein A on its surface, and Protein A binds strongly to the constant region of the heavy chains of gamma-globulins, it is possible that false positive results may be obtained from non-specific binding of the antibodies to Protein A. To overcome this difficulty, the immunoassay wells were coated with bacteria as described above, but prior to the addition of the antibodies to the bacteria- coated wells, the MAbs were incubated with a solution of recombinant Protein A conjugated to HRP (Zymed Laboratories Cat. No.
  • the plate was again washed with PBS-T, and 95 ⁇ l of gamma-specific Rabbit anti-Mouse IgG, conjugated to horseradish peroxidase (HRP) (Zymed Laboratories) was added to all wells.
  • HRP horseradish peroxidase
  • the plate was again covered and incubated in a draft-free environment for 30-60 minutes at room temperature.
  • the plate was washed with PBS-T and 100 ⁇ l of TMB substrate solution was added to each well. After a 15 minute incubation at room temperature in the dark, 100 ⁇ l of TMB stop solution was added to all wells and the absorbance of each well was measured using a Molecular Devices V max plate reader with a 450 nm filter.
  • Activity Assays Activity Assays
  • Antibodies that bind to an antigen may not necessarily enhance opsonization or enhance protection from infection. Therefore, an opsonization assay was used to determine the functional activities of the antibodies.
  • An opsonization assay can be a colorimetric assay, a chemiluminescent assay, a fluorescent or radiolabel uptake assay, a cell- mediated bactericidal assay, or any other appropriate assay known in the art which measures the opsonic potential of a substance and thereby identifies reactive immunoglobulin.
  • an infectious agent, a eukaryotic cell, and the opsonizing substance to be tested, or an opsonizing substance plus a purported opsonizing enhancing substance are incubated together.
  • the opsonization assay is a cell- mediated bactericidal assay.
  • an infectious agent such as a bacterium, a phagocytic cell, and an opsonizing substance, such as immunoglobulin, are incubated together.
  • Any eukaryotic cell with phagocytic or binding ability may be used in a cell-mediated bactericidal assay.
  • phagocytic cells are macrophages, monocytes, neutrophils, or any combination of these cells. Complement proteins may be included to promote opsonization by both the classical and alternate pathways.
  • the amount or number of infectious agents remaining after incubation determines the opsonic ability of an antibody. The fewer the number of infectious agents that remain after incubation, the greater the opsonic activity of the antibody tested.
  • opsonic activity is measured by comparing the number of surviving bacteria between two similar assays, only one of which contains the antibody being tested.
  • opsonic activity is determined by measuring the number of viable organisms before and after incubation with a sample antibody. A reduced number of bacteria after incubation in the presence of antibody indicates a positive opsonizing activity.
  • positive opsonization is determined by culturing the incubation mixture under appropriate bacterial growth conditions. Any reduction in the number of viable bacteria comparing pre-incubation and post-incubation samples, or between samples that contain immunoglobulin and those that do not, is a positive reaction.
  • Neutraphil-Mediated Opsonophagocytic Bactericidal Assay The assay was performed using neutrophils isolated from adult venous blood by sedimentation using PMN Separation Medium (Robbins Scientific catalog no. 1068-00-0). Forty microliters of antibody, serum, or other immunoglobulin source, was added at various dilutions to replicate wells of a round-bottom microtiter plate. Forty microliters of neutrophils (approximately 10 6 cells per well) was then added to each well, followed immediately by approximately 3 x 10 4 mid-log phase bacteria (S. epidermidis strain Hay, ATCC 55133 or S.
  • Nasal Colonization Assay The mouse nasal colonization model for S. aureus was based on the work of Kiser et al. (11). Briefly, streptomycin resistant S. aureus type 5 is grown on high salt Columbia agar (Difco) to promote capsule formation. The bacteria are washed with sterile saline (0.9% NaCl in water) to remove media components and resuspended at ⁇ 10 8 bacteria/animal dose in saline (0.9% NaCl in water) containing various concentrations and combinations of anti-staphylococcal or irrelevant control MAbs.
  • the bacteria are pelleted and resuspended in a final volume of 10 ⁇ l per animal dose in either saline or saline containing antibody.
  • Mice that have been maintained on streptomycin- containing water for 24 hours are sedated with anesthesia. Staphylococci are instilled into the nares of the mice by pipetting without contacting the nose.
  • mice were immunized with a subcutaneous (sc) dose of 0.1 ml (5 ⁇ g per mouse).
  • sc subcutaneous
  • PBS 873 ⁇ l
  • PepG 7 mg/ml suspension
  • Alhydrogel 120 ⁇ l
  • Each mouse received an sc dose of 0.1 ml (5 ⁇ g of PepG per mouse).
  • mice were immunized with a 50 ⁇ g/ml solution containing 50% Alum adjuvant (Pierce Cat. No.77161) in PBS (0.2 ml/mouse). Sera from the immunized mice were tested by ELISA as described above. As shown in Table 1 , serum from mouse 8813 bound most strongly to PepG. This mouse was given a final, pre-fusion, intraperitoneal boost of 10 ⁇ g PepG in PBS three days prior to the generation of hybridomas. Table 1
  • Hybridomas were prepared by the general methods of Shulman, Wilde and Kohler and Bartal, A.H. and Hirshaut (2, 28). Spleen cells from mouse 8813 were mixed with SP2/0 mouse myeloma cells (ATCC No. CRL1581) at a ratio of 10 spleen cells per SP2/0 cell, pelleted by centrifugation (400 x g, 10 minutes at room temperature) and washed in serum free DMEM (Hyclone cat. no. SH30081.01 , or equivalent).
  • the supernatant was removed and fusion of the cell mixture was accomplished in a sterile 50 ml centrifuge conical by the addition of 1 ml of a 50% w/v solution of polyethylene glycol (PEG; mw 1500; Boehringer Mannheim cat. no. 783641) over a period of 60-90 seconds. Serum free medium was then added slowly in successive volumes of 1 , 2, 4, 8, 16 and 19 ml. The hybridoma cell suspension was gently resuspended into the medium and the cells pelleted by centrifugation (500 x g, 10 minutes at room temperature).
  • PEG polyethylene glycol
  • the supernatant was removed and the cells resuspended in RPMI 1640, supplemented with 10% heat-inactivated fetal bovine serum, 0.05 mM hypoxanthine and 16 ⁇ M thymidine (HT medium; Life Technologies cat. no. 11067-030, or equivalent).
  • HT medium heat-inactivated fetal bovine serum
  • 0.05 mM hypoxanthine and 16 ⁇ M thymidine 16 ⁇ M thymidine
  • One hundred microliters of the hybridoma suspension cells were plated into 96-well tissue culture plates. Eight wells (column 1 of plate A) received approximately 2.5 X 10 4 SP2/0 cells in 100 ⁇ l. The SP2/0 cells served as a control for killing by the selection medium added 24 hours later.
  • Clone 99-110FC12 IE4 was grown in an Integra Biosystems Culture system, designed to produce high quantities of immunoglobulin in culture supernatants. Supernatant from the IE4 clone was tested by ELISA on wells coated with methanol-fixed S. epidermidis strain Hay, PepG, and LTA. As shown in Table 5, the antibody bound strongly to S. aureus PepG, but not to the methanol-fixed bacteria, or to S. aureus LTA. Table 5
  • Bacillus subtilis HR (gift of Howard Roger, University of Kent, UK) vegetative cell walls were made as previously described under stringent conditions, using lipopolysaccharide-free materials (6, 38), which are herein incorporated for any purpose). Proteins were removed from the peptidoglycan by treatment with pronase, and teichoic acid and other attached polymers were removed by treatment with HF (48% v/v) for 24 h at 4°C. The insoluble peptidoglycan was pelleted by centrifugation (13,000 g, 5 min, 4°C) and resuspended in distilled water to 2 mg/ml PepG. This step was repeated once.
  • the peptidoglycan was then pelleted and resuspended in 50 mM Tris HCI pH7.5 to 2 mg/ml PepG, and this step was repeated once. Finally, the peptidoglycan was pelleted and resuspended in distilled water to 2 mg/ml PepG three more times. The peptidoglycan was resuspended at about 10 mg/ml in distilled water and stored at -20°C.
  • PepG preparations were analyzed as previously described by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), which revealed no evidence of contaminating protein (39).
  • SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
  • the purity of the peptidoglycan was further verified by amino acid analysis of hydrolyzed PepG, which gave only the expected amino acids, and by reverse phase chromatography analysis of enzymatically digested material, both assays performed as previously described (1). This level of purity had previously not been ensured during the production of anti-peptidoglycan antibodies.
  • Peptidoglycan conjugate was made as per the manufacturers protocol for the Imject SuperCarrier EDC System for Peptides (Pierce, cat. no. 77152).
  • Muropeptides were made by Cellosyl digestion.
  • Cellosyl is a muramidase that cleaves the bond between N-acetylmuramic acid and N- acetylglucosamine in the glycan backbone of PepG.
  • Complete cellosyl digestion of PepG results in the production of small, soluble muropeptides.
  • One milliliter of 11.5mg/ml purified peptidoglycan was harvested by centrifugation (13,000 g, 5 min, 4°C) and resuspended in 1 ml conjugation buffer, supplied with the Imject SuperCarrier EDC System for Peptides (Pierce, cat. no. 77152).
  • Hybridomas were prepared by the general methods of Shulman, Wilde and Kohler and Bartal and Hirshaut (2, 28). Spleen cells from immunized mice 1 and 2 were pooled and were mixed with SP2/0 mouse myeloma cells at a ratio of 5 spleen cells per SP2/0 cell, pelleted by centrifugation (770 xg, 5 minutes at 30 ° C) and washed in serum-free RPMI. One milliliter of PEG 1500 (50% in 75 mM HEPES, Boehringer cat. no. 783 641 ) was added over 1 minute, followed by 1 ml of RPMI over 1 minute, and then 9 ml of RPMI over 2 minutes.
  • Cells were then pelleted by centrifugation at 430 xg for 15 minutes at 30 ° C. Cells were resuspended in RPMI-1640/HAT (1 ml of 50X HAT concentrate (Invitrogen cat no. 21060-017) in 50ml RPMI- 1640) containing 20% FCS at approximately 1 x 10 6 cells/ml. One hundred microliters of cell suspension was added to each well of ten 96-well plates and grown at 37 ° C. Unfused SP2/0 cells were used as a selection control and died 5 days after plating.
  • PepG from Bacillus subtilis, Staphylococcus aureus, Streptococcus mutans, Bacillus megaterium, Enterococcus faecalis, Staphylococcus epidermidis, and Listeria monocytogenes was purified as described in Example 2.
  • One milliliter of each PepG (10 mg/ml) in 25 mM sodium phosphate buffer pH5.6 was digested with 250 ⁇ g/ml cellosyl (Hoechst AG) for 15 hours at 37 ° C. The samples were boiled for 3 minutes to stop the reaction and insoluble material was removed by centrifugation (14,000 xg for 8 minutes at room temperature). The soluble cellosyl-digested PepG was stored at -20C.
  • Staphylococcal PepG has a unique pentaglycine crossbridge, which can be cleaved by lysostaphin, a glycine-gycine endopeptidase.
  • Lysostaphin 25 ⁇ g/ml; Sigma Cat No. L0761
  • S. aureus was also digested without lysostaphin.
  • ELISA to determine antibody affinities for PepG and cellosyl-digested PepG
  • 96-well immunoassay plates (NUNC Immunoplate Maxisorp) were coated with 100 ⁇ g/ml poly-L-lysine (Sigma Chemicals, cat. no. P6407) in 0.05 M carbonate/bicarbonate buffer pH 9.6 (0.015 M Na 2 C0 3 , 0.035 M NaHC0 3 , pH 9.6, hereafter referred to as carbonate buffer) for 1 hour at room temperature.
  • the carbonate buffer was removed, and the wells were washed once with carbonate buffer.
  • the wells were then coated with 100 ⁇ l 5 ⁇ g/ml purified PepG substrate, or cellosyl-digested PepG substrate, in carbonate buffer overnight at 4 ° C.
  • the substrate solution was removed, and the wells were washed twice with PBS-T.
  • the wells were then blocked with 150 ⁇ l PBS-T containing 0.2% w/v bovine gelatin (Sigma cat. no. A7030; blocking buffer) for 2 hours at 37 ° C.
  • the blocking buffer was removed and the wells were washed four times with PBS-T.
  • Table 6 demonstrates that the PepG antibodies described are not identical, as each shows a different range of specificity and affinity for the different PepG substrates. Specifically, 702PG, MAb-11-232.3, and MAb-11 - 248.2 show high affinity for S. aureus PepG, and low affinity for B. subtilis PepG, while the antibodies produced by BB4/A4 and BB4/A5 (also called MAb-BB4/A4 and MAb-BB4/A5) show the reverse specificity. MAb-BB4/A4 and MAb-BB4/A5 also show high affinity for S. epidermidis, while the others do not. Table 6
  • Bacillus subtilis 168 HR was a gift from Howard Roger, University of Kent, U.K. Staphylococcus aureus 8325/4 was a gift from Richard Novick, Skirball Institute, NY,
  • Streptococcus mutans LTII was a gift from Roy Russell, University of Newcastle, U.K.
  • Bacillus megaterium KM was a gift from Keith Johnstone, University of Cambridge,
  • Staphylococcus epidermidis 138 was a gift from Paul Williams, University of Nottingham, U.K.
  • S. aureus PepG has a higher level of O-acetylation on glucosamine residues than PepG from B. subtilis, suggesting that this O- acetylation may be important for the binding of antibodies 702PG, MAb-11- 232.3, and MAb-11 -248.2, and may negatively affect the binding of MAb- BB4/A4 and MAb-BB4/A5.
  • EXAMPLE 4 Binding of the Monoclonal Antibodies to LTA, PepG and Staphylococci
  • MAb-11 -232.3, MAb-11-248.2, MAb-11-569.3, and MAb-99- 110FC12 IE4 were assayed for binding to S. aureus PepG, S. aureus LTA, and to methanol-fixed S. aureus and methanol-fixed S. epidermidis.
  • a human/mouse chimeric anti-LTA antibody referred to as A110, was included in the assays as a positive control for LTA and S. epidermidis binding.
  • a description of the production and chimerization of A110 can be found in U.S. Patent Application Serial No. 09/097,055, filed June 15, 1998.
  • MAb-11 -232.3 and MAb-11 -248.2 which were raised to whole UV-killed S. aureus, are specific for PepG on the surface of the bacteria.
  • MAb-11-569.3 which was also raised to UV-killed S. aureus, shows much weaker binding to PepG, and no binding to LTA, indicating that it may be specific for PepG, although it may also be specific for another surface antigen, but cross-react with PepG.
  • MAb-99- 110FC12 IE4 which was raised to purified S. aureus PepG, binds to PepG, but not LTA, quite strongly.
  • the IgM antibodies (from hybridomas 11-248.2 and 99-1 10FC12 IE4) were not tested against S. aureus, because the immunoassay Protein A method used for the S. aureus-coated plates does not work with IgM antibodies, which do not bind to protein.
  • Table 9 The immunoassay Protein A method used for the S. aureus-coated plates does not work with IgM antibodies, which do not bind to protein.
  • peptidoglycan is a cell wall component found in Gram-positive bacteria.
  • MAb-1 1 -232.3, MAb-11-248.2, and MAb-99-110FC12 IE4 bind PepG strongly and do not bind LTA, another cell wall component common to Gram-positive bacteria.
  • MAb-11 -569.3 binds PepG less strongly in an ELISA (Table 7) than it binds S. aureus type 5 in a methanol-fixed ELISA (Table 10). Differences observed in the binding of the MAbs may be due to the specific epitope bound by the MAbs and the presentation of that epitope in protein and whole-bacteria ELISAs.
  • MAb-11 -569.3 may bind to a different antigen, but cross-react with PepG.
  • MAb-11 -232.3, 11-248.2 ascites and MAb-11 -569.3 also bind in an ELISA assay to S. epidermidis strain Hay.
  • MAb-11-232.3 and MAb-11-569.3 also bind in an ELISA assay to S. aureus (binding of 11 - 248.2 ascites in the ELISA to S. aureus could not be determined).
  • the lack of binding of 99-110FC12 IE4 supernatant to S. epidermidis strain Hay in the ELISA suggests that this antibody binds an epitope found on S. aureus PepG, but not expressed or available for binding in S. epidermidis strain Hay.
  • EXAMPLE 5 The Opsonophagocytic Activity of the Monoclonal Antibodies
  • Antibodies that bind to an antigen may not necessarily enhance opsonization or enhance protection from infection. Therefore, a neutrophil mediated bactericidal assay was used to determine the functional activity of anti-PepG MAb against S. aureus and S. epidermidis strain Hay.
  • Neutrophils (PMNs) were isolated from adult venous blood by using PMN separation medium (Robbins Scientific Cat. No. 1068-00-0). Forty microliters of PMNs were added to round-bottomed wells of micro titer plates (approximately 2 X 10 6 cells per well) with approximately 3 x 10 4 mid-log phase bacteria. Human serum, treated with Protein G and Protein L to remove antibodies that bind to S. aureus and S.
  • epidermidis strain Hay was used as a source of active complement. Forty microliters of antibody was added to the wells at various dilutions and the plates were incubated at 37°C with constant, vigorous shaking. Samples of 10 ⁇ l were taken from each well at zero time and after 2 hours of incubation. Each was diluted, vigorously vortexed to disperse the bacteria, and cultured on blood agar plates overnight at 37°C to quantitate the number of viable bacteria.
  • Results are presented as percent reduction in numbers of bacterial colonies observed compared to control samples.
  • 99-110FC12 IE4 supernatant was active against S. aureus type 5, but not against S. epidermidis strain Hay as shown in Table 11.
  • Hybridoma 99-110FC12 IE4 was produced by immunization of mice with PepG, while hybridomas 11 -232.3, 11-248.2, and 11 -569.3, were produced by immunizing mice with UV-inactivated whole S. aureus.
  • Each of the anti-PepG MAbs from the hybridoma lines was tested for activity in the opsonophagocytic bactericidal assay.
  • A110 which binds LTA, was also included in the assay.
  • the MAbs produced by 11 -232.3 and 11- 569.3 are mouse lgG 3 , kappa light chain antibodies, and were purified before use.
  • A110 which is a human/mouse chimeric antibody with a human IgGi and a kappa light chain, was also purified before use.
  • MAb-99-110FC12 IE4 and MAb-11 -248.2 are mouse IgM, kappa light chain antibodies and were used as either cell culture supernatant (99-110FC12 IE4) or as ascites (11 - 248.2).
  • Opsonic studies were performed to determine if the MAbs enhanced phagocytosis and killing of both groups of staphylococci.
  • each of the anti-PepG antibodies demonstrated enhanced killing of S. aureus.
  • PMNs were mixed with complement but without antibody, killing of the S. aureus was less than 20%.
  • addition of MAb-11 -232.3 or MAb-11-569.3 at 100 ⁇ g/ml resulted in killing of 76% and 82%, respectively.
  • the use of undiluted ascites from 11 - 248.2 (a mouse IgM) resulted in killing of 89%, while 75% killing was obtained with neat supernatant from 99-110FC12 IE4 (also a mouse IgM).
  • A110 binds strongly to S. aureus LTA (Table 8), and to methanol-fixed S. aureus (Table 10), it shows very weak opsonization of S. aureus in this assay.
  • Table 12A shows very weak opsonization of S. aureus in this assay.
  • Streptomycin resistant S. aureus type 5 (SA5, 1 to 3x10 8 bacteria/mouse) was preincubated for 1 hour in saline (0.9% NaCl in water), saline containing MAb-11 -232.3 (2-3 mg purified IgG per mouse dose of 1 - 3x10 8 bacteria) or saline containing Medi 493 (2-3 mg purified IgG/mouse dose of 1-3x10 8 bacteria).
  • mice Following preincubation, the bacteria were pelleted and resuspended in saline (10 ⁇ l/mouse dose), , in saline containing MAb-11 - 232.3 (10 ⁇ l/mouse dose), or in saline containing Medi 493 (10 ⁇ l/mouse dose).
  • Eight or nine mice each were intranasally instilled with SA5 in saline, SA5 in MAb-11 -232.3, or SA5 in Medi 493. After seven days, the mice were sacrificed and the nasal tissue dissected and plated on Columbia blood agar and tryptic soy agar containing streptomycin to determine colonization. Table 14 shows that MAb-11-232.3 reduced staphylococcal nasal colonization in mice, but that an anti-RSV MAb, Medi 493, had no effect.
  • Table 14 shows that MAb-11-232.3 reduced staphylococcal nasal colonization in mice, but that an anti-RSV MAb, Medi 493, had no effect.
  • Table 14 shows that both the number of mice colonized, and the number of colonies, are reduced in an antibody-specific manner by anti-S. aureus surface antigen-specific MAb-11 -232.3. All of the mice in the saline and the irrelevant chimeric IgG control groups were colonized with S. aureus, but only three out of eight mice were colonized in the MAb-11 -232.3 group. This reduction in the number of mice colonized demonstrates that the administered MAb 11-232.3 is protective because five of the - eight mice are free from bacterial colonization. The number of colonies recovered per mouse in the MAb-11 -232.3 group was also dramatically reduced as compared with the other two groups.
  • the saline control group exhibited an average of 70 colonies in the nine mice colonized and the irrelevant antibody control group exhibited even greater number of average colonies, 187, in the nine mice colonized.
  • only three of the eight animals in the treated group exhibited any sign of colonization and that level of colonization, an average of 8 colonies per mouse nose, was greatly reduced.
  • Such a reduction in colonies recovered is similarly profylactically beneficial in vivo. Therefore, the administered anti-PepG MAb is protective from S. aureus nasal colonization.
  • aureus peptidoglycan may demonstrate similar inhibitory effects on S. aureus colonization as described above. Studies are in progress to affirm the effectiveness of MAb-11-248.2 and MAb-11-569.3 in the in vivo mouse model described above.
  • the final volume of the suspension was 50 ml, resulting in a cell concentration of 4.5 cells/ml.
  • Two hundred microliters of the cell suspension was added to each well of two 96-well tissue culture dishes. The cultures were incubated for 10 days at 37°C in a humidified atmosphere of 5% C0 in air. The presence of clones was verified by microscopic observation of single foci of cells in individual wells. Approximately 40% of all wells had growing clones of 11-232.3. When tested by ELISA, all supernatants bound peptidoglycan.
  • Four cultures, 11 - 232.3 -IG9, -IE9, -IH7 and -IB6 were expanded and cryopreserved. The binding of these four clones to peptidoglycan and LTA is shown in Table 15.
  • the MAb produced by hybridoma 11-232.3 IE9 was subsequently designated M130. TABLE 15
  • Figure 1 shows the strategy for cloning the variable region genes.
  • Table 17 shows the sequences of the oligonucleotide primers used for the procedures (SEQ ID NOS: 5-12).
  • the total RNA (2 ⁇ g) was converted to cDNA by using Superscript ll-MMLV Reverse Transcriptase (Life Technologies) and mouse Kappa-specific primer (JSBX-18; SEQ ID NO: 8; Sigma-Genosys) and a mouse heavy chain-specific primer (JSBX-25A; SEQ ID NO: 9; Sigma-Genosys) according to the manufacturer's procedures (see Table 12 for primer sequences).
  • the first strand cDNA synthesis products were purified using a Centricon-30 concentrator device (Amicon).
  • PCR amplification reactions contained template DNA, 30 pmoles of the appropriate primers (JSBX-11A, -12A and -18 for light chains; SEQ ID NOS: 6-8; JSBX-5 and -25A for heavy chains; SEQ ID NO: 5 and SEQ ID NO: 9), 2.5 units of ExTaq polymerase (PanVera), 1x ExTaq reaction buffer, 200 ⁇ M each dNTP, 2mM MgCI 2 .
  • the template was denatured by an initial incubation at 96°C for 3 min.
  • PCR products (approximately 400 base pairs) were then cloned into bacterial vector pGEM T (Promega), a T/A style cloning vector, following the manufacturer's procedures using a 3:1 insert to vector molar ratio.
  • pGEM T Promega
  • One half (5 ⁇ l) of the ligation reactions were used to transform Ultracompetent XU BIue cells (Stratagene) as per the manufacturer's procedure.
  • Bacterial clones containing plasmids with DNA inserts were identified using diagnostic restriction enzyme digestions with Dralli and BsiWI (for heavy chain clones) or Dralli and EcoRV (for light chain clones) (New England Biolabs).
  • Plasmids containing inserts of the appropriate size were then sequenced.
  • the pGEM vector containing the M130 heavy chain variable region is referred to as pJSB18-6, and the pGEM vector containing the M130 light chain variable region is referred to as pJSB4-4.
  • the final consensus DNA sequence of the light and heavy chain variable regions is shown in Figure 2 (SEQ ID NO: 2 and SEQ ID NO: 4, respectively).
  • variable region of M130 were then subcloned into a mammalian expression plasmid vector for production of recombinant chimeric mouse/human antibody molecules under the control of CMV transcription promoters.
  • the variable region of M130 is fused directly to the human lgGi constant domain.
  • the light chain of M130 has a mouse Kappa intron domain 3' of the variable region coding sequence. After splicing, the variable region becomes fused to a human Kappa constant region exon.
  • the selectable marker for both vectors in mammalian cells is Neomycin (G418).
  • variable region gene fragments were re-amplified by PCR using primers that adapted the fragments for cloning into the expression vector ( Figure 1 , Table 17).
  • the heavy chain front primer (JSBX-44; SEQ ID NO: 11) includes a 5' tail that encodes the C-terminus of the heavy chain leader and a BsiWI restriction site for cloning, while the heavy chain reverse primer (JSBX-45; SEQ ID NO: 12) adds a 3' EcoRI restriction site for cloning. This results in the addition of two amino acids, glutamine (E) and phenylalanine (F) between the heavy chain variable region and the human lgGi constant region.
  • E glutamine
  • F phenylalanine
  • the light chain front primer (JSBX-11 A; SEQ ID NO: 6) introduces a 5' tail that encodes the two C-terminal amino acids of the light chain leader and an Agel restriction site for cloning purposes.
  • the light chain reverse primer (JSBX-27; SEQ ID NO: 10) adds a 3' DNA sequence for the joining region-Kappa exon splice junction followed by a Ss/BI restriction site for cloning.
  • PCRs were performed as described above, using pJSB18-6 as a template for the heavy chain and pJSB4-4 as a template for the light chain. Following a three minute incubation at 96°C the PCR perimeters were 30 thermal cycles of 58°C for 30 sec, 70°C for 30 sec, and 96°C for 1 min.
  • the heavy chain PCR product was digested with BsiW ⁇ and EcoRI (New England Biolabs), purified using a Nucleospin PCR Purification column (Clontech), per the manufacturer's instructions, and ligated into SsM/l/EcoRI/P TMI digested and gel-purified pJRS383, using the Takara Ligation Kit (Panvera), per the manufacturer's procedure.
  • the ligation mix was then transformed into XLIBIue cells (Stratagene); clones were selected and screened for the correct insert, resulting in mammalian expression vector pJSB22 ( Figure 3).
  • the light chain PCR product (approximately 350 base pairs) was digested with Age ⁇ and Bs ⁇ (New England Biolabs), purified using a Nucleospin PCR Purification column (Clontech), as described by the manufacturer. This fragment was then ligated into pJRS384 that had been Age ⁇ /Bs ⁇ /Xcm ⁇ digested and gel-purified, using the Takara Ligation Kit (Panvera), per the manufacturer's procedure. The ligation mix was then transformed into XLI BIue cells (Stratagene); clones were selected and screened for the correct insert, resulting in mammalian expression plasmid pJSB6.1 (see Figure 4).
  • the plasmid pJSB6.1 was digested with BamH ⁇ and Nhe ⁇ (New England Biolabs) and purified using a Nucleospin PCR Purification column (Clontech), as described by the manufacturer.
  • the plasmid pJSB22 was digested with Bgl ⁇ and Nhe ⁇ (New England Biolabs), separated on an agarose gel and the fragment containing the heavy chain expression domain was isolated using a Nucleospin Gel Fragment DNA Purification column (Clontech).
  • the plasmid pLG1-MEGA was transfected into COS-7 (ATCC no. CRL 1651) cells using Superfect (Qiagen) in 6 well tissue culture dishes as described by the manufacturer. After two days the supernatant was assayed for the production of chimeric antibody and for the capability for the expressed antibody to bind to S. aureus peptidoglycan antigen as follows.
  • a goat anti-human kappa-HRP (Zymed) conjugate was diluted 1 :800 in the sample/conjugate diluent (0.02 M Tris pH 7.4, 0.25 M NaCI 2 , 2% gelatin, 0.1% Tween-20).
  • sample/conjugate diluent 0.1% Tris pH 7.4, 0.25 M NaCI 2 , 2% gelatin, 0.1% Tween-20.
  • One hundred microliters was added to the samples, and then incubated on a plate rotator for 60 minutes at room temperature.
  • the samples were washed seven times, as above and then incubated with 100 ⁇ L ⁇ vell of TMB substrate (BioFx, cat. no. TMBW-0100-01 ) for ⁇ 1 minute at room temperature.
  • the reaction was stopped with 100 ⁇ LJwell of TMB Stop reagent (BioFx, cat. no.
  • the supernatants were then assayed for the ability of the expressed antibodies to bind to peptidoglycan.
  • 8-well strips (Maxisorp F8; Nunc, Inc.) were coated with a 5 ⁇ g/ml solution of S. aureus peptidoglycan (prepared by the method set forth in Example 2) in carbonate coating buffer, pH 9.5 (0.1 M sodium bicarbonate) overnight at 4°C. Plates were washed once with PBS. One hundred microliters of culture supernatant dilutions were applied to duplicate wells and allowed to incubate for 60 minutes on a plate rotator at room temperature. The plates were washed seven times with Wash solution.
  • monoclonal antibodies M110, M130, MAb-11-230.3, MAb-11 -232.3, MAb-11 -391.4, MAb-11-557.3, MAb-11-564.4, MAb-11-580.5, and MAb-11 -586.3 were diluted to 3 ⁇ g/ml in PBS.
  • Hybridomas 11-230.3, 11- 232.3, 11 -391.4, 11 -557.3, 11 -564.4, 11 -580.5, and 11 -586.3 were derived from mice that had been immunized with whole UV-killed S. aureus.
  • MAb-11 -230.3, MAb-11-232.3, MAb-11 -557.3, MAb-11 -564.4, and MAb-11-586.3 have been previously shown to bind to PepG, while MAb- 11 -391.4 binds to LTA, and MAb-11 -580.5 binds to an unknown epitope on S. aureus.
  • These MAbs were used to coat four columns of Nunc Maxisorp Stripwells (Nunc Cat # 469949), and are referred to as "capture" antibodies. Coating of each capture antibody was accomplished by adding 100 ⁇ l of the 3 ⁇ g/ml solution to the appropriate wells and incubating overnight (18-26 hours) at room temperature.
  • the unbound material was then removed from the wells by washing four times with PBS-T.
  • S. aureus peptidoglycan prepared by S. Foster as described in Example 2
  • PBS-T PBS-T without peptidoglycan was added to the wells of the other two columns.
  • Table 18 shows the results of the capture assay using a battery of capture MAbs, followed by PepG, and then A130 as the detection MAb. After coating a well with MAb-11-230.2, MAb-11-232.3, MAb-11-557.3, MAb- 11-564.4, or MAb-11 -586.3, and incubating with PepG, the detection antibody, A130, binds to the captured PepG on the plate. If an anti-LTA antibody, such as that produced by hybridoma 391.4, or M110, is used to capture, A130 does not bind, presumably because the capture antibody failed to bind PepG.
  • an anti-LTA antibody such as that produced by hybridoma 391.4, or M110
  • MAb-11-580.5 which is of unknown specificity, also fails to capture significant PepG, as evidenced by the lack of binding by A130.
  • A130 which has identical variable regions as A130, is to capture PepG, A130 binds strongly to the plate.
  • PepG Sandwich Assay Capture with anti-S. aureus MAbs and Detection with A130
  • Table 19 shows the results of the sandwich assay using A110 as the capture antibody, followed by LTA, and then a battery of detection MAbs.
  • This assay confirms that the antibodies that are believed to bind to PepG do not in fact bind to possible LTA contaminants in the PepG preparation.
  • A110 was used as the capture antibody to capture LTA on the plate.
  • the anti-LTA antibodies including those produced by hybridoma 391.4, and M110, show strong binding to the captured LTA.
  • MAb-11-580.5 which is of unknown specificity, does not bind to the captured LTA.
  • M110 does not capture a contaminant in the PepG preparation that is recognized by M130
  • the following sandwich assay was performed. M110 was bound to plates as the capture antibody, LTA or PepG was then bound to the plates, followed by either A110 or A130 as the detection antibody.
  • Nunc Maxisorp Stripwells (Nunc Cat # 469949) were coated with 100 ⁇ l of M110 at 3 ⁇ g/ml and incubated overnight (18-26 hours) at room temperature. The unbound material was then removed from the wells by washing four times with PBS-T. Four columns of wells then received 100 ⁇ l/well of LTA solution (Sigma Cat #2515 diluted to 1 ⁇ g/ml in PBS-T), four columns received 100 ⁇ l/well of PepG solution (10 ⁇ g/ml in PBS-T), and four columns received PBS-T alone. The wells were incubated for 30-60 minutes at room temperature and then washed four times with PBS-T.
  • LTA solution Sigma Cat #2515 diluted to 1 ⁇ g/ml in PBS-T
  • PepG solution 10 ⁇ g/ml in PBS-T
  • PBS-T alone
  • Table 20 shows the results of the sandwich assay using M110 as the capture antibody, followed by PepG or LTA, and then A110 or A130 as the detection antibody. These results demonstrate again that M110 does not capture an antigen that can be bound by A130. Furthermore, this result demonstrates that the PepG preparation used in these assays does not contain appreciable levels of LTA, as capture of the PepG with anti-LTA M110 antibody does not result in sufficient captured LTA to show binding of A110 above background levels. Table 20
  • RNA is used to produce a cDNA library of antibody heavy and light chain fragments expressed on the surface of bacteriophage. These libraries can be used to probe against the antigen of interest (i.e., PepG) and the phage that bind, because of the antibody expressed on the surface, are then isolated. The DNA encoding the variable regions is sequenced and cloned for antibody expression.
  • Another method of producing human antibodies employs "humanized" mice. These transgenic mice have had their own antibody genes replaced with a portion of the human antibody gene complex so that upon inoculation with antigen, they produce human antibodies (48, 50, 51 , 52, 54). The antibody producing cells that result can then be incorporated into the standard hybridoma technology for the establishment of specific monoclonal antibody producing cell lines.
  • Recombinant human antibodies are also produced by isolating antibody-producing B cells from human volunteers that have a robust anti- PepG response. Using fluorescence activated cell sorting (FACS) and fluorescently labeled PepG, cells producing the anti-PepG antibodies can be separated from the other cells. The RNA can then be extracted and the sequence of the reactive antibody variable regions determined (49, 53). The DNA sequence of the functional variable regions can be synthesized or cloned into mammalian expression vectors for large-scale human recombinant antibody production.
  • FACS fluorescence activated cell sorting
  • Monoclonal antibodies were also raised against B. subtilis PepG.
  • Hybridomas BB4/A4 and BB4/A5 produce IgG antibodies that bind to B. subtilis PepG (Example 2).
  • the affinity of the monoclonal antibodies produced by BB4/A4, BB4/A5, 11 -232.3, 11-248.2, 11-569.3, and antibody 702 PG, which is purified from hybridoma 11-232.3, were tested for binding to PepG from a number of different bacteria in an ELISA assay.
  • MAb-BB4/A4 and MAb-BB4/A5 which were produced from the same mouse, bound strongly to PepG from B. subtilis and S.
  • A110, MAb-11 -232.3, MAb-11-248.2, MAb-99-110FC12 IE4, and MAb-11 -569.3 were tested for binding to S. aureus PepG in an ELISA assay.
  • MAb-11 -232.3, MAb-11-248.2, and MAb-99-110FC12 IE4 which were raised to either whole UV-killed S. aureus or to S. aureus PepG, bound strongly to S. aureus PepG.
  • MAb-11-569.3 bound weakly to PepG, although it was also raised to whole UV-killed S. aureus, indicating that it may bind to an epitope other than PepG on the surface of the bacteria.
  • the anti-LTA antibody, A110 did not bind to S. aureus PepG (Example 4, Table 7). In a similar assay to measure binding of the antibodies to S. aureus LTA, only A110 showed appreciable binding (Example 4, Table 8). The results demonstrate that antibodies raised to whole UV-killed S. aureus may in fact be specific for PepG on the surface of the bacteria.
  • A110, MAb-11 -232.3, and MAb-11 -569.3 were tested for binding to methanol-fixed S. aureus.
  • MAb-11 -232.3 and MAb-11-569.3 bound strongly, as they were raised to whole UV-killed S. aureus.
  • A110 also bound to methanol-fixed S. aureus, although it was raised to heat-killed S. epidermidis, indicating that it may bind to an epitope that is conserved between the two bacteria (Example 4, Table 10).
  • Hybridoma 99-110FC12 IE4 supernatant was tested for opsonic activity against S. aureus and S. epidermidis in the presence of PMNs and complement, which was derived from human serum that had been depleted of antibodies to S. aureus and S. epidermidis.
  • MAb-99-110FC12 IE4 was opsonic against S. aureus, but not against S. epidermidis (Example 5, Table 11).
  • MAb-99-110FC12 IE4 binds to S. aureus PepG, but not to whole S. epidermidis, suggesting a correlation between binding ability and opsonic activity.
  • MAb-11 -232.2, MAb-11 -569.3, MAb-11 -248.2, each of which was raised to whole UV-killed S. aureus, as well as MAb-99-110FC12 IE4, which was raised to purified S. aureus PepG, and A110 were tested in a similar opsonophagocytic assay against S. aureus type 5.
  • the anti- LTA antibody, A110 which was raised against LTA from S. epidermidis, showed only 23% killing (Example 5, Table 12).
  • A110 bound strongly to both S. aureus LTA and whole methanol-fixed S. aureus, it was not strongly opsonic against S. aureus.
  • the non-chimerized version of A110, M110 was somewhat more opsonic against S. aureus in a previous assay (Example 5, Table 12B).
  • This variation is likely due to assay to assay variations and dosage effects, rather than differences in activity between the chimerized and non-chimerized antibodies, because A110 retains its activity against S. epidermidis (Example 5, Table 13).
  • MAb-11-232.3 was tested for its ability to block nasal colonization in mice. After preincubation of S. aureus type 5 with MAb-11 - 232.3, only 3 out of 8 mice were colonized by S. aureus, as compared to 9 out of 9 mice in the control groups. Furthermore, of the mice that were colonized, the mice that received S. aureus that had been preincubated with MAb-11 - 232.3 had one-tenth the number of bacterial colonies as control mice (Example 6, Table 14). These results suggest that MAb-11-232.3, which binds to and is opsonic against S. aureus, is able to block nasal colonization by the bacteria, and is also able to reduce the number of bacteria in mice that are colonized.
  • Hybridoma 11-232.3 was subcloned, and the antibody produced by subclone 11-232.3 IE9, M130, was further analyzed. M130 was tested for binding to a number of different bacteria in a live bacteria ELISA assay. M130 bound to three different strains of live S. aureus, but did not bind to S. hemolyticus or S. epidermidis (Example 7, Table 16). These results are consistent with the methanol-fixed bacteria ELISAs, in which MAb-11 -232.3 bound strongly to S. aureus, but weakly to S. epidermidis. Therefore, although MAb-11.232.3 and M130 are specific for S.
  • variable regions of M 130 were cloned and human/mouse chimeric antibodies were produced that have the M130 variable regions and human constant regions (Examples 8 and 9). These chimeric antibodies, referred to as A130, retained the ability to bind to S. aureus PepG (Example 10, Figure 7). These human/mouse chimeric antibodies are expected to have a reduced HAMA response in humans, which may be therapeutically advantageous.
  • sandwich assays were conducted to confirm that the anti-PepG antibodies of the invention are in fact specific for PepG, and do not bind to contaminants in PepG preparations.
  • a battery of antibodies were used to capture PepG on a plate, and then A130 was used as a detection antibody to detect the captured PepG (Example 11 , Table 18).
  • A130 was used as a detection antibody to detect the captured PepG (Example 11 , Table 18).
  • antibodies that are known to bind to PepG were able to capture PepG, as detected by binding of A130 antibody.
  • Antibodies that bind to LTA did not capture an antigen that could be detected by A130, indicating that A130 does not bind to LTA.
  • anti-LTA A110 antibody was used to capture LTA on a plate, which was then detected with the same battery of antibodies as was used for capture in the first assay (Example 11 , Table 19).
  • the anti-LTA antibodies were able to detect the LTA that was captured by A110.
  • the anti-PepG antibodies were unable to detect an antigen captured by A110, suggesting that they do not bind to LTA.
  • M1 10 was used to capture either LTA or PepG on a plate, and the captured antigen was then detected with either A110 or A130 (Example 11 , Table 20).
  • M110 was not able to capture an antigen from either the PepG or LTA preparations that was detectable by A130. M110 was able to capture LTA that was detectable by A110, however. Significantly, M110 was not able to capture sufficient LTA from the PepG preparation to allow measurable detection by A110, suggesting that the PepG preparation is substantially free of LTA. This level of purity in a PepG preparation has not previously been demonstrated.
  • the antibodies of the invention can block or alleviate nasal colonization. These antibodies may therefore be useful protective molecules in the fight against antibiotic-resistant Gram-positive bacterial infections.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux protecteurs qui se fixent au peptidoglycane de bactéries Gram-positif. Lesdits anticorps se fixent également à ces bactéries, favorisant la phagocytose et la mort des bactéries in vitro et bloquant la colonisation nasale par les bactéries Gram-positifs in vivo. L'invention concerne également des anticorps humains, humanisés et chimériques. L'invention concerne en outre des régions variables de chaîne lourde et de chaîne légère d'un anticorps.
EP02806494A 2001-12-21 2002-12-23 Anticorps monoclonaux multifonctionnels diriges contre le peptidoglycane de bacteries gram-positif Withdrawn EP1470237A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34344401P 2001-12-21 2001-12-21
US34180601P 2001-12-21 2001-12-21
US343444P 2001-12-21
US341806P 2001-12-21
PCT/US2002/041032 WO2003059259A2 (fr) 2001-12-21 2002-12-23 Anticorps monoclonaux multifonctionnels diriges contre le peptidoglycane de bacteries gram-positif

Publications (2)

Publication Number Publication Date
EP1470237A2 true EP1470237A2 (fr) 2004-10-27
EP1470237A4 EP1470237A4 (fr) 2006-02-01

Family

ID=26992674

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02806494A Withdrawn EP1470237A4 (fr) 2001-12-21 2002-12-23 Anticorps monoclonaux multifonctionnels diriges contre le peptidoglycane de bacteries gram-positif

Country Status (5)

Country Link
EP (1) EP1470237A4 (fr)
JP (2) JP2005524624A (fr)
AU (2) AU2002364740A1 (fr)
CA (1) CA2469714A1 (fr)
WO (1) WO2003059259A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
EA021767B1 (ru) * 2006-06-06 2015-08-31 Круселл Холланд Б.В. Антитела человека с киллерной активностью в отношении энтерококков и стафилококков и их применение
HUE027099T2 (hu) 2006-06-06 2016-08-29 Crucell Holland Bv Humán kötõmolekulák staphylococcus elleni ölõaktivitással és alkalmazásuk
JP2008255084A (ja) * 2007-04-04 2008-10-23 Isako Hashimoto 抗花粉症剤または食品
CN102089005A (zh) * 2008-05-12 2011-06-08 斯特罗克斯生物制药有限责任公司 金黄色葡萄球菌特异性抗体制剂
US20100260752A1 (en) * 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
EP2872535A1 (fr) 2012-07-16 2015-05-20 Pfizer Inc. Saccharides et leurs utilisations
US9809645B2 (en) 2013-03-12 2017-11-07 Zenyaku Kogyo Kabushikikaisha Anti-Staphylococcus antibody, method for manufacturing same, and usage of same
CN106749652A (zh) * 2017-03-14 2017-05-31 天津喜诺生物医药有限公司 一种金黄色葡萄球菌肽聚糖的多克隆抗体
JP7366922B2 (ja) * 2018-10-25 2023-10-23 島津ダイアグノスティクス株式会社 集菌方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596769A (en) * 1984-03-05 1986-06-24 Temple University Monoclonal antibodies to peptidoglycan and methods of preparing same
WO1998057994A2 (fr) * 1997-06-16 1998-12-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Anticorps opsoniques, monoclonaux protecteurs, et chimeres specifiques a l'acide lipoteichoique des bacteries gram positif
WO2000056357A2 (fr) * 1999-03-19 2000-09-28 Nabi Antigene et vaccin de staphylocoque
GB2356402A (en) * 2000-07-22 2001-05-23 Michael G Morgan radiolabelled peptidoglycan antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596769A (en) * 1984-03-05 1986-06-24 Temple University Monoclonal antibodies to peptidoglycan and methods of preparing same
WO1998057994A2 (fr) * 1997-06-16 1998-12-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Anticorps opsoniques, monoclonaux protecteurs, et chimeres specifiques a l'acide lipoteichoique des bacteries gram positif
WO2000056357A2 (fr) * 1999-03-19 2000-09-28 Nabi Antigene et vaccin de staphylocoque
GB2356402A (en) * 2000-07-22 2001-05-23 Michael G Morgan radiolabelled peptidoglycan antibodies

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CLARK L A ET AL: "Opsonic activity of intravenous immunoglobulin preparations against Staphylococcus epidermidis.", JOURNAL OF CLINICAL PATHOLOGY AUG 1986 LNKD- PUBMED:3745476, vol. 39, no. 8, August 1986 (1986-08), pages 856-860, ISSN: 0021-9746 *
DRYLA AGNIESZKA ET AL: "Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 12, no. 3, 1 March 2005 (2005-03-01), pages 387-398, XP009094535, ISSN: 1071-412X, DOI: DOI:10.1128/CDLI.12.3.387-398.2005 *
DZIARSKI R: "Ontogenic development of proliferative and polyclonal antibody and autoantibody responses to staphylococcal peptidoglycan, protein A and cell walls in mice." DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY. WINTER 1985, vol. 9, no. 1, January 1985 (1985-01), pages 119-130, XP002355350 ISSN: 0145-305X *
FROST A J ET AL: "THE EFFECT ON INFLAMMATION OF THE BOVINE MAMMARY GLAND OF VACCINATION WITH A CELL WALL EXTRACT OF STAPHYLOCOCCUS AUREUS" JOURNAL OF VETERINARY MEDICINE. SERIES B - ZENTRALBLATT FUER VETERINAERMEDIZIN. REINE B, PAUL PAREY, BERLIN, DE, vol. 35, no. 9, 1988, pages 687-694, XP000973782 ISSN: 0931-1793 *
HENCKAERTS ET AL: "Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children", VACCINE, ELSEVIER LTD, GB, vol. 25, no. 13, 13 March 2007 (2007-03-13), pages 2518-2527, XP005919810, ISSN: 0264-410X, DOI: DOI:10.1016/J.VACCINE.2006.09.029 *
PETERSON P K ET AL: "The key role of peptidoglycan in the opsonization of Staphylococcus aureus." THE JOURNAL OF CLINICAL INVESTIGATION. MAR 1978, vol. 61, no. 3, March 1978 (1978-03), pages 597-609, XP002355351 ISSN: 0021-9738 *
SEDER ROBERT A ET AL: "T-cell quality in memory and protection: implications for vaccine design", NATURE REVIEWS. IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 8, no. 4, 1 April 2008 (2008-04-01), pages 247-258, XP009117658, ISSN: 1474-1733, DOI: DOI:10.1038/NRI2274 *
See also references of WO03059259A2 *
WERGELAND H I ET AL: "Antibodies to staphylococcal peptidoglycan and its peptide epitopes, teichoic acid, and lipoteichoic acid in sera from blood donors and patients with staphylococcal infections." JOURNAL OF CLINICAL MICROBIOLOGY. JUN 1989, vol. 27, no. 6, June 1989 (1989-06), pages 1286-1291, XP002355360 ISSN: 0095-1137 *

Also Published As

Publication number Publication date
AU2002364740A1 (en) 2003-07-30
AU2009210372A1 (en) 2009-09-10
CA2469714A1 (fr) 2003-07-24
JP2005524624A (ja) 2005-08-18
EP1470237A4 (fr) 2006-02-01
WO2003059259A3 (fr) 2004-06-17
WO2003059259A2 (fr) 2003-07-24
AU2009210372B2 (en) 2012-07-26
JP2010013454A (ja) 2010-01-21

Similar Documents

Publication Publication Date Title
US20080014202A1 (en) Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
AU2009210372B2 (en) Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US7777017B2 (en) Nucleic acids encoding opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
AU2009202762B2 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
JP4691225B2 (ja) グラム陽性細菌のリポテイコ酸に特異的なオプソニン的かつ防御的モノクローナルおよびキメラ抗体
US20030224000A1 (en) Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
AU2010200341A1 (en) Wall Teichoic Acid as a Target for Anti-Staphylococcal Therapies and Vaccines
JP6371758B2 (ja) 抗ブドウ球菌抗体、その製造方法並びにその使用
JP2005514053A6 (ja) グラム陽性細菌のリポタイコ酸に特異的なオプソニン性モノクローナルおよびキメラ抗体
US10100103B2 (en) Opsonic and protective monoclonal antibodies against gram-positive pathogens
AU2012254925B2 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
AU2002365440A1 (en) Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040702

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FISCHER, GERALD, W.

Inventor name: STINSON, JEFFREY, R.

Inventor name: FOSTER, SIMON

Inventor name: KOKAI-KUN, JOHN, F.

Inventor name: SCHUMAN, RICHARD F.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1069852

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/12 19950101ALN20051205BHEP

Ipc: A61K 39/02 19850101ALI20051205BHEP

Ipc: C12N 5/20 19900101ALI20051205BHEP

Ipc: A61P 31/04 20000101ALI20051205BHEP

Ipc: A61K 39/40 19850101AFI20051205BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20051220

17Q First examination report despatched

Effective date: 20100122

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110806

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1069852

Country of ref document: HK